A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

Inclusion criteria

• Voluntary participation and written informed consent;
• 18-75 years older, no gender limitation;
• Eastern Cooperative Oncology Group (ECOG) score: 0-1;
• With a life expectancy ≥ 3 months;
• Pathologically diagnosed advanced solid tumor;
• Be able to provide fresh or archived tumour tissue;
• At least one measurable lesion according to RECIST v1.1;
• Adequate bone marrow reserve and organ function;
• Contraception is required during clinical trials, and pregnancy tests must be negative for women of childbearing age within 7 days before the first dose.

Exclusion criteria

• Meningeal metastasis history or clinical symptoms of central nervous system metastasis;
• Previous or co-existing malignancies;
• Spinal cord compression that was not treated radically by surgery and/or radiotherapy was excluded;
• Uncontrollable tumor-related pain;
• Previously received antiboy-coupled drug therapy with topoisomerase I inhibitor toxin; Previously received EGFR/c-Met double antibody;
• Received systemic antitumor therapy before the first dose;
• Have undergone major surgery other than diagnosis or biopsy within 28 days prior to initial dosing; Minor traumatic surgery within 7 days prior to first dosing;
• For the first time, a study was conducted to treat patients with radiation therapy exceeding the prescribed dose before study treatment;
• Received Other investigational drugs treatments 4 weeks prior to the initiation of the study treatment;
• Unresolved CTCAE 5.0>grade 2 toxicities from previous anticancer therapy;
• A history of interstitial pneumonia/non-infectious pneumonia;
• Accompanied by uncontrolled pleural effusion and pericardial effusion; Moderate or severe ascites with clinical symptoms;
• Study the presence of intestinal obstruction or the presence of signs or symptoms of intestinal obstruction 6 months before first dosing;
• With poorly controlled or severe cardiovascular disease;
• Active hepatitis B, hepatitis C;
• Patients with a history of immunodeficiency;
• Severe infection 30 days before the first dose.